The HCPLive Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.
December 4th 2023
Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Expert Illustrations & Commentaries™: A Family Physicians’ Guide to Migraine Treatment – Emerging Therapies and Evolving Paradigms
View More
PER® Postgame™: MS Meeting Updates – Integrating the Latest Data to Optimize Care in the COVID-19 Era
View More
Medical Crossfire®: What Strategies Can the Care Team Implement to Optimize the Management of Pediatric Patients with NF1?
View More
Visualizing the Role of Antipsychotics in the Management of Schizophrenia: What is the Role of TAAR1?
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
BURST CME™: Taking ALS Management to the Next Level
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application
Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.
New Research Seeks Explanation of Antidepressant Placebo Effect
The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.
Psychosocial Familial Factors Associated With Symptom Severity for Pediatric ADHD
Parenting stress, negative parenting practices, broken parental partnership, critical life events, parental psychopathologies, socioeconomic status, and single-parent family were all significantly associated with ADHD symptom severity.